The acquisition will achieve the synergies between Viva Biotech and SYNthesis, regarding to the CRO business in the global market, which is of great st...
Dogma Therapeutics, a Viva Biotech Portfolio Company, has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca. An ora...
Invested and incubated by Viva Bioinnovator, VivaVision announced the company had submitted the application for phase II clinical trial of VVN001 to F...
The Group proactively implemented containment measures to seek opportunities behind such crisis and accelerate the integration of research.
Viva Biotech and Langhua Pharmaceutical reached strategic acquisition agreement，Accelerating the Integration and Escalation of the Service Chain of I...
This A+ round of financing will be used to accelerate ABM Therapeutics further clinical research and development of existing preclinical projects.
" As long as you can provide new solutions to the unmet clinical needs, it should be defined as innovation."
Both parties will collate their respective expertise to promote the incubation of innovative biotech startups.
Aim to expand the reach of structure-based drug discovery by generating de novo crystal structures of high-value targets.
Viva Biotech has been regarding environmental protection and social responsibility as an integral part of our development.
The goal of the ABM-1310,the company's lead candidate, the study is to determine the optimal dose for phase 1b/2 studies.
Viva BioInnovator (VBI) held its 1st Demo Day e-congress. 8 of VBI's 50 portfolio companies joined the event as speakers.
QureBio aims to solve the intractable cancer, autoimmune diseases, metabolic diseasesand other difficult diseases and other difficult diseases.
ABM-1310 is a highly selective and potent BRAF inhibitors as shown in human kinase panel screen and cellular assay screen.
QurAlis Corporation intends to use this funding to support the development of new therapies for ALS and FTD.
Viva Biotech Announces 2019 Annual Results, with a rapid accumulation of CFS customers and forntier projects incubated.
Viva Biotech Announced 2019 Annual Results, Accelerating the Integration of Innovative Drugs Industrial Chain.
JPM week is globally recognized as the most important and largest event of the year for the biotech industry.
DTx Pharma will use this round of financing to accelerate its proprietary platform to promote the R&D of RNA drugs.
Viva Biotech was invited to the ‘Future Healthcare VB 100 Summit’ and awarded the ‘Top 10 Public Companies 2019’.
Relying on our strong drug discovery platform, Viva Biotech will provide services to more biotech startups with promising future and help realizing their gre...
Viva Biotech successfully held an Annual Appreciation Reception in Boston, US to thank our clients for their continued support and collaboration.
Viva is mentoring and supporting these companies from the very beginning of their journey, when they are in desperate need of investment and resources.
Viva Biotech Chief Business Officer and Head of Viva BioInnovator, David Xu, Ph.D., was featured on the “China Cross-Border Partnerships” Pa...
Viva Biotech Announces 2019 Interim Results, Two Engine Driven Business Model Fueling Steady Full-range Growth in Business.
MS. Yinghong Gao gave a presentation on “SBDD, FDBB, ASMS and SPR-inspired Medicinal Chemistry”, representing Viva Biotech.
QureBio's goal is to create new drugs that could treat many indications such as cancer, autoimmune, and metabolic diseases for patients all around the world.
Members of the VBI BioInnovator (VBI) team went to San Diego and San Francisco for three days of action-packed meetings and receptions.
On Nov. 14th, 2018, Viva Biotech held its inaugural Partnering Reception in San Diego, one of the biotech hubs in the U.S,